丁苯酞联合尿激酶静脉溶栓治疗急性脑梗死的疗效及安全性研究
|
摘要
目的探讨丁苯酞联合尿激酶静脉溶栓在急性脑梗死治疗中的应用价值。方法选取我院2015年9月~2017年9月收治的72例急性脑梗死患者为研究对象,根据治疗方式的不同将其分为对照组和观察组,各36例,均接受常规治疗,其中对照组在此基础上加用尿激酶静脉溶栓治疗,而观察组则给予丁苯酞联合尿激酶静脉溶栓方案,比较两组临床效果。结果治疗后,对照组治疗总有效率为77.8%,明显低于观察组的94.4%,差异有统计学意义(P <0.05);治疗前,观察组、对照组的神经功能缺损评分、日常生活能力指数比较差异无统计学意义(P> 0.05),治疗后,观察组和对照组的神经功能缺损评分、日常生活能力指数均有所改善,但观察组改善程度最显著,差异有统计学意义(P<0.05);两组血管再通率差异无统计学意义(P>0.05);观察组并发症发生率(13.9%)明显低于对照组(38.9%),差异有统计学意义(P <0.05)。结论给予急性脑梗死患者丁苯酞联合尿激酶静脉治疗方案,既可提高治疗效果,又可改善神经缺损功能和日常生活能力,同时有利于提高血管再通率和治疗安全性,降低并发症发生率,值得推广应用。
Objective To explore the application value of butylphthalide combined with intravenous thrombolysis with urokinase in treatment of acute cerebral infarction. Methods 72 patients with acute cerebral infarction who were admitted and treated in our hospital from September 2015 to September 2017 were selected as research objects.According to different treatment methods,they were divided into the control group and the observation group,with36 cases in each group.Patients In two groups were all given routine treatment.On basis of it,the control group was treated with intravenous thrombolysis with urokinase while the observation group was given butylphthalide combined with intravenous thrombolysis with urokinase.The clinical curative effects of the two groups were compared. Results After treatment,the total effective rate of the control group was 77.8%,which was significantly lower than that of the observation group(94.4%).The difference was statistically significant(P < 0.05).Before treatment,there was no statistically significant difference in neurological deficit scores and daily living ability index between the observation group and the control group(P > 0.05).After treatment,the neurological deficit score and daily living ability index of the observation group and the control group were all improved,but the improvement degree of the observation group was the more significant.The differences were statistically significant(P < 0.05).There was no statistically significant difference in vascular recanalization rate between the two groups(P > 0.05).The incidence of complications in the observation group(13.9%)was significantly lower than that in the control group(38.9%).The difference was statistically significant(P < 0.05). Conclusion Butylphthalide combined with intravenous thrombolysis with urokinase in treatment of patients with acute cerebral infarction can improve the curative effect,improve the function of neurological deficit and daily living ability,improve the vascular recanalization rate and safety of treatment and reduce the incidence of complications.It is worth promoting and applying.
Objective To explore the application value of butylphthalide combined with intravenous thrombolysis with urokinase in treatment of acute cerebral infarction. Methods 72 patients with acute cerebral infarction who were admitted and treated in our hospital from September 2015 to September 2017 were selected as research objects.According to different treatment methods,they were divided into the control group and the observation group,with36 cases in each group.Patients In two groups were all given routine treatment.On basis of it,the control group was treated with intravenous thrombolysis with urokinase while the observation group was given butylphthalide combined with intravenous thrombolysis with urokinase.The clinical curative effects of the two groups were compared. Results After treatment,the total effective rate of the control group was 77.8%,which was significantly lower than that of the observation group(94.4%).The difference was statistically significant(P < 0.05).Before treatment,there was no statistically significant difference in neurological deficit scores and daily living ability index between the observation group and the control group(P > 0.05).After treatment,the neurological deficit score and daily living ability index of the observation group and the control group were all improved,but the improvement degree of the observation group was the more significant.The differences were statistically significant(P < 0.05).There was no statistically significant difference in vascular recanalization rate between the two groups(P > 0.05).The incidence of complications in the observation group(13.9%)was significantly lower than that in the control group(38.9%).The difference was statistically significant(P < 0.05). Conclusion Butylphthalide combined with intravenous thrombolysis with urokinase in treatment of patients with acute cerebral infarction can improve the curative effect,improve the function of neurological deficit and daily living ability,improve the vascular recanalization rate and safety of treatment and reduce the incidence of complications.It is worth promoting and applying.
引文
[1]梁茜茜,张庆,李莉,等.阿司匹林联合氯吡格雷治疗急性脑梗死的临床研究[J].中国临床药理学杂志,2016,32(16):1446-1448.
[2]刘小玲,袁金艳,杨建萍.PDCA在急性脑梗死患者溶栓治疗的护理质量持续改进中的应用[J].临床医学研究与实践,2016,1(27):166-167.
[3]陈芬芬,郑纯,丁连娥,等.眼血流动力学参数对颈动脉狭窄型缺血性脑血管疾病诊断价值研究[J].临床眼科杂志,2016,24(1):24-27.
[4]张金武.氯吡格雷联合阿司匹林在急性脑梗死治疗中的疗效评定[J].中国实用神经疾病杂志,2016,19(18):27-29.
[5]许晓敬,贾阳娟,韩凝,等.NIHSS评分对急性脑梗死颅内大动脉闭塞的预测价值[J].脑与神经疾病杂志,2016,24(9):544-548.
[6]黄美玲,王玉龙,王尧.康复医学专科医疗联合体中脑卒中患者康复疗效的同质化研究[J].中国康复医学杂志,2017,32(6):618-623.
[7]廖晓凌,王伊龙,潘岳松,等.急性大脑中动脉闭塞性脑梗死静脉溶栓后血管再通与预后[J].中国卒中杂志,2016,11(10):824-828.
[8]李晓波,黄敏,陈蓓蕾,等.急性脑梗死合并心房颤动患者的重组组织型纤溶酶原激活剂静脉溶栓治疗[J].中华老年医学杂志,2016,35(1):22-26.
[9]胡晓,瞿浩,李世容,等.静脉溶栓联合亚低温治疗对急性脑梗死患者疗效及可能作用机制的研究[J].中国神经精神疾病杂志,2016,42(1):15-21.
[10]朱智瑞,楚英杰,徐予.陈旧性脑梗死患者发生急性心肌梗死的冠脉病变特征和临床特点[J].中国心血管病研究,2017,15(11):1015-1017.
[11]赵秀欣,穆利春,马丽芳.rt-PA静脉溶栓治疗急性脑梗死临床分析[J].中国循证心血管医学杂志,2016,8(4):486-488.
[12]黄才英,刘本德,刘金平.尿激酶溶栓治疗急性脑梗死后出血的临床效果分析[J].重庆医学,2016,45(32):4502-4504.
[13]刘飞.尿激酶静脉溶栓治疗急性脑梗死效果探讨[J].中国实用医刊,2016,43(3):18-19.
[14]王义振,孙秋瑞.丁苯酞软胶囊联合尿激酶溶栓治疗急性脑梗死的效果分析[J].中外医学研究,2016,14(14):136-137.
[15]吕风亚.氟伐他汀联合丁苯酞软胶囊治疗急性脑梗死的疗效及对血清IL-6水平的影响[J].中国老年学杂志,2015,35(18):5154-5155.
[2]刘小玲,袁金艳,杨建萍.PDCA在急性脑梗死患者溶栓治疗的护理质量持续改进中的应用[J].临床医学研究与实践,2016,1(27):166-167.
[3]陈芬芬,郑纯,丁连娥,等.眼血流动力学参数对颈动脉狭窄型缺血性脑血管疾病诊断价值研究[J].临床眼科杂志,2016,24(1):24-27.
[4]张金武.氯吡格雷联合阿司匹林在急性脑梗死治疗中的疗效评定[J].中国实用神经疾病杂志,2016,19(18):27-29.
[5]许晓敬,贾阳娟,韩凝,等.NIHSS评分对急性脑梗死颅内大动脉闭塞的预测价值[J].脑与神经疾病杂志,2016,24(9):544-548.
[6]黄美玲,王玉龙,王尧.康复医学专科医疗联合体中脑卒中患者康复疗效的同质化研究[J].中国康复医学杂志,2017,32(6):618-623.
[7]廖晓凌,王伊龙,潘岳松,等.急性大脑中动脉闭塞性脑梗死静脉溶栓后血管再通与预后[J].中国卒中杂志,2016,11(10):824-828.
[8]李晓波,黄敏,陈蓓蕾,等.急性脑梗死合并心房颤动患者的重组组织型纤溶酶原激活剂静脉溶栓治疗[J].中华老年医学杂志,2016,35(1):22-26.
[9]胡晓,瞿浩,李世容,等.静脉溶栓联合亚低温治疗对急性脑梗死患者疗效及可能作用机制的研究[J].中国神经精神疾病杂志,2016,42(1):15-21.
[10]朱智瑞,楚英杰,徐予.陈旧性脑梗死患者发生急性心肌梗死的冠脉病变特征和临床特点[J].中国心血管病研究,2017,15(11):1015-1017.
[11]赵秀欣,穆利春,马丽芳.rt-PA静脉溶栓治疗急性脑梗死临床分析[J].中国循证心血管医学杂志,2016,8(4):486-488.
[12]黄才英,刘本德,刘金平.尿激酶溶栓治疗急性脑梗死后出血的临床效果分析[J].重庆医学,2016,45(32):4502-4504.
[13]刘飞.尿激酶静脉溶栓治疗急性脑梗死效果探讨[J].中国实用医刊,2016,43(3):18-19.
[14]王义振,孙秋瑞.丁苯酞软胶囊联合尿激酶溶栓治疗急性脑梗死的效果分析[J].中外医学研究,2016,14(14):136-137.
[15]吕风亚.氟伐他汀联合丁苯酞软胶囊治疗急性脑梗死的疗效及对血清IL-6水平的影响[J].中国老年学杂志,2015,35(18):5154-5155.